RxDoctor Payments Data

Lisa Bean, NP

Family · Conneaut, OHNPI 1629461082

Payments from drug & device makers

$1,014in general payments, 2019–2025

Across 49 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$256
  • AstraZeneca$210
  • E.r. Squibb & Sons, L.L.C.$121
  • Jazz Pharmaceuticals Inc.$98
  • Inspire Medical Systems, Inc.$77
  • Fisher & Paykel Healthcare Inc$50
  • plus $203 from 6 others

What the payments were for

  • Food & beverage$1,014100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,014 in reported general payments places this provider in the 70th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$42,156
Medicare patients
276
Services billed
384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter617$486,260
Breztri AerosphereBudesonide/Glycopyr/Formoterol242$183,533
Spiriva RespimatTiotropium Bromide89$59,106
Stiolto RespimatTiotropium Br/Olodaterol Hcl86$50,369
Breo ElliptaFluticasone/Vilanterol96$47,529
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr85$46,332
SymbicortBudesonide/Formoterol Fumarate81$19,279
Bevespi AerosphereGlycopyrrolate/Formoterol Fum24$15,862
Albuterol Sulfate HfaAlbuterol Sulfate622$15,629
Combivent RespimatIpratropium/Albuterol Sulfate22$14,379
Fluticasone-SalmeterolFluticasone Propion/Salmeterol120$13,349
Arnuity ElliptaFluticasone Furoate38$12,155
Advair HfaFluticasone Propion/Salmeterol25$12,149
Roflumilast83$10,624
DuleraMometasone/Formoterol22$9,328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$256$592,276836 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$210$218,673347 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$32$123,854197 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,812 family providers in Ohio.

Other family in Conneaut

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →